Skip to main content
Premium Trial:

Request an Annual Quote

Genomenon, OmniTier to Integrate Genome Analysis Technologies

NEW YORK – Genomenon said Tuesday that it will integrate its Mastermind genomics literature search engine into OmniTier's CompStor Insight platform, a specialized appliance for tertiary analysis of next-generation sequencing data. The partnership will give CompStor Insight users a list of published articles relevant to their searches and help them quickly find the scientific evidence in Mastermind, the companies said.

CompStor Insight is targeted at research and clinical users who are looking to understand the relationships between multiple genomes, including those who are trying to diagnose rare diseases. OmniTier, which has twin headquarters in Milpitas, California, and Rochester, Minnesota, introduced the product around the virtual American Society of Human Genetics conference in October.

"With this partnership, OmniTier's CompStor Insight users will be able to directly link out to relevant Mastermind articles when investigating specific variants of interest," Mike Klein, CEO of Ann Arbor, Michigan-based Genomenon, said in a statement. Klein said that the integration will reduce the cost of genomic analysis for "mainstream" clinical diagnosis and genomic screening facilities.

"Our customers have been asking us to partner with Genomenon to give them access to the world's most comprehensive source for genomic variant literature," added OmniTier CEO Hemant Thapar. "With this partnership, we will bring the power of Mastermind variant evidence lookup to CompStor's fast, low-cost, on-premises-based variant interpretation."

Genomenon said that Mastermind support will be available to all CompStor Insight users later this month.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.